Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg®
10 February 2013 | By Novo Nordisk
“We are convinced that Tresiba® and Ryzodeg® offer significant benefits...”
List view / Grid view
10 February 2013 | By Novo Nordisk
“We are convinced that Tresiba® and Ryzodeg® offer significant benefits...”
31 January 2013 | By Novo Nordisk
Sales growth of 18% driven by Victoza®, NovoRapid® and Levemir®...
21 January 2013 | By Novo Nordisk
“We look forward to making Tresiba® and Ryzodeg® available to many people with diabetes in Europe”
25 December 2012 | By Novo Nordisk
Novo Nordisk announced that the Japanese Ministry of Health, Labour and Welfare has approved Ryzodeg®...
19 December 2012 | By Novo Nordisk
Novo Nordisk announced the completion of the phase 3a programme for IDegLira...
3 December 2012 | By Novo Nordisk
Novo Nordisk announced that Ryzodeg® has passed the review...
27 November 2012 | By Novo Nordisk
New data analyses...
14 November 2012 | By Novo Nordisk
Novo Nordisk has for the second year in a row just been ranked among the top 25 best multinational workplaces...
14 November 2012 | By Novo Nordisk
New numbers on the prevalence of diabetes have been launched...
9 November 2012 | By Novo Nordisk
“The positive vote from the Advisory Committee marks an important step..."
31 October 2012 | By Novo Nordisk
Sales grew 18% driven by Victoza®, NovoRapid® and Levemir®...
25 October 2012 | By Novo Nordisk
“This meeting will focus on the cardiovascular safety of two products..."
19 October 2012 | By Novo Nordisk
Tresiba® and Ryzodeg® receive positive opinions...
19 October 2012 | By Novo Nordisk
Japan’s PMDA has published an assessment report of Tresiba®...
16 October 2012 | By Novo Nordisk
Novo Nordisk announced the submission of the regulatory application for turoctocog alfa...